Castle Biosciences (CSTL) Revenue (2018 - 2026)

Castle Biosciences has reported Revenue for 9 years, with the latest figure at $103.5 million in Q2 2026.

• Quarterly Revenue rose 20.14% year-over-year to $103.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $357.3 million (up 3.18% YoY) and the FY2025 annual result came in at $344.2 million, up 3.66% from the prior year.
• Revenue rose to $103.5 million in Q2 2026 per CSTL's latest filing, from $83.7 million in the prior quarter.
• Over five years, Revenue peaked at $103.5 million in Q2 2026 and troughed at $26.9 million in Q1 2022.
• A 5-year average of $67.8 million and a median of $78.0 million in 2024 frame the typical range for Revenue.
• The sharpest annual moves came in 2024 and 2026: Revenue soared 73.59% in 2024, then decreased 4.9% in 2026.
• Over 5 years, Revenue stood at $38.3 million in 2022, then jumped by 72.47% to $66.1 million in 2023, then soared by 30.54% to $86.3 million in 2024, then advanced by 0.81% to $87.0 million in 2025, then advanced by 19.0% to $103.5 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $103.5 million, $83.7 million, and $87.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.